Selected Portfolio Company Press Releases
May 6 2013
Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019
May 5 2013
Successful five-year follow-up data from SRS™ pilot study
May 2 2013
Acceleron and Shire Conclude Collaboration on ACE-031
May 2 2013
Insulet to Develop New Version of the OmniPod Insulin Pump for Use With Humulin R U-500 Concentrated Insulin for People With Type 2 Diabetes
May 2 2013
NxStage Reports First Quarter 2013 Financial Results
May 1 2013
STUDY DEMONSTRATES SIGNIFICANT PAIN REDUCTION WITH DFINE STAR™ TUMOR ABLATION SYSTEM IN SPINAL METASTASES
April 30 2013
NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
April 30 2013
Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL
April 29 2013
BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
April 25 2013
NxStage Names Robert G. Funari Chairman Of The Board
April 24 2013
Pharma data miner Treato scores $14.5M
April 23 2013
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
April 23 2013
InspireMD Receives Approval from US Food and Drug Administration to Begin US Regulatory Trial
April 18 2013
Good Start Genetics® Reports Clinical Data Showing Its Carrier Screening Technology Detects Mutations in Cystic Fibrosis and Other Diseases Missed by Traditional Approaches
April 18 2013
Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics
April 17 2013
Durata Therapeutics Closes Public Offering of Common Stock
April 17 2013
NEW STUDIES SHOW CLINICALLY SIGNIFICANT PALLIATION OF PAINFUL SPINAL METASTASES WITH DFINE STAR™ TUMOR ABLATION SYSTEM
April 16 2013
InspireMD Closes $25 Million Underwritten Public Offering
April 12 2013
KIMS has been declared as the winner of “Golden Peacock Business Excellence Award” for the year 2013
April 10 2013
Pieris and Sanofi Broaden Existing Collaboration
April 10 2013
Marshfield Food Safety, LLC Streamlines Food Safety Testing and Achieves Greater Efficiencies with Roka Bioscience Atlas® System
April 10 2013
BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of Leukemia
April 9 2013
Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
April 8 2013
NxStage Completes Move to Direct Sales In UK
April 8 2013
METHYLGENE PRESENTS PRECLINICAL DATA ON MG516 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
April 8 2013
Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa®
April 5 2013
Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
April 4 2013
Aragon Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer
April 3 2013
Crown Bioscience, Inc. and Horizon Discovery Announce Exclusive Two Year Agreement to Offer Combined Solutions for In Vivo Drug Discovery Model Development
March 28 2013
Biodel Completes Enrollment in Phase 2 Clinical Trial of Ultra-Rapid-Acting Insulin Candidate BIOD-123 for the Treatment of Diabetes
March 27 2013
New Published Analysis Finds Opioid-Related Adverse Events Increase Hospital Stays, Costs of Care and Risks of Readmission and Mortality
March 27 2013
Analysis of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost and Higher Likelihood of Readmission
March 27 2013
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
March 26 2013
Acceleron Receives Two FDA Orphan Designations for ACE-536
March 25 2013
arGEN-X announces preclinical development of ARGX-112 for dermatology
March 22 2013
Singulex Digital Single Molecule Counting: A new concept in assay detection
March 22 2013
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
March 21 2013
GOOD START GENETICS REPORTS CLINICAL DATA AT THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS (ACMG)
March 20 2013
BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia
March 18 2013
METHYLGENE REPORTS RESULTS OF PHASE II TRIAL OF MGCD290
March 15 2013
AVITIDE, INC., SECURES SERIES A FINANCING TO COMMERCIALIZE NOVEL BIOPHARMACEUTICAL AFFINITY PURIFICATION TECHNOLOGY
March 12 2013
Medigus Signed a Distribution Agreement in China
March 12 2013
Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
March 12 2013
Cerapedics Adds New Board Member Antony Koblish
March 11 2013
Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2012 Financial Results
March 7 2013
NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
March 7 2013
Pacira Pharmaceuticals, Inc. Reports 2012 Financial Results
March 7 2013
Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
March 7 2013
Acceleron Initiates Phase 2 Study of ACE-536 to Treat Patients with Beta-Thalassemia
March 4 2013
Medigus completed $8M private placement by OrbiMed
March 4 2013
Rapedics Announces 10,000th Patient Treated With i-FACTOR™ Peptide Enhanced Bone Graft
February 28 2013
Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations
February 28 2013
BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company's Main Therapeutic Pipeline as BL-9010
February 27 2013
Insulet Reports Fourth Quarter and Full Year 2012 Results
February 26 2013
GROWING BODY OF EVIDENCE SUPPORTS USE OF DFINE’S TARGETED RADIOFREQUENCY ABLATION™ (t-RFA) FOR TREATMENT OF SPINAL TUMORS
February 26 2013
Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
February 26 2013
Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
February 20 2013
Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
February 20 2013
Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
February 8 2013
OxOnc Announces Agreement With Pfizer to Develop Crizotinib as First-Line and Second-Line Treatment for Patients With ROS1-Positive Non-Small Cell Lung Cancer
February 6 2013
BioLineRx Announces Offering of American Depositary Shares
February 5 2013
Glaukos Corporation Raises $30 Million in Series F Financing
February 5 2013
Acceleron Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Ovarian Cancer
February 5 2013
Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma
February 4 2013
ViewRay Appoints Chris A. Raanes President and CEO
February 1 2013
Supernus Launches Oxtellar XR(TM) in the United States
January 29 2013
Acceleron Initiates Phase 2 Study of ACE-536 to Treat Anemia in Patients with Myelodysplastic Syndromes
January 25 2013
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 24 2013
Biodel Reports Positive Top-Line Results From Clinical Study of Ultra-Rapid-Acting Insulin Analog Candidates
January 24 2013
Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)
January 18 2013
NxStage® to Report Fourth Quarter and Full Year 2012 Financial Results
January 17 2013
Pacira Pharmaceuticals, Inc. Announces Pricing of $110 Million Private Offering of Convertible Senior Notes
January 8 2013
Adimab Expands Collaborations with Merck and Lilly
January 7 2013
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products
January 7 2013
ArGEN-X expands its therapeutic antibody alliance with Shire
January 7 2013
Adimab Announces New Discovery Collaboration with Kyowa Hakko Kirin
January 4 2013
Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis
January 4 2013
Aragon Wins Key Legal Ruling Against Medivation
January 3 2013
Insulet Corporation Announces the Sale of $85 Million of Common Stock
December 14 2012
Next-Generation OmniPod(R) Insulin Pump Cleared by FDA
December 14 2012
Glaukos selected as a 2012 Red Herring Top 100 Global Award Winner
December 12 2012
Cerapedics Secures $19 Million Series C
December 7 2012
Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
December 6 2012
Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring While Continuing to Assess Strategic Alternatives
November 29 2012
Supernus Announces Pricing of Public Offering
November 29 2012
CardiAQ™ Valve Technologies, Inc. Completes $37.3 Million Series B Round of Financing Led by OrbiMed Advisors LLC
November 28 2012
Selecta (RUS) LLC becomes RUSNANO’s first foreign portfolio company in the pharmaceutical sector to open a research center in Russia
November 28 2012
Selecta and Sanofi Sign Global Collaboration
November 21 2012
METHYLGENE CLOSES CDN.$26.1 MILLION PRIVATE PLACEMENT
November 20 2012
Supernus Announces Positive Phase IIb Results on SPN-810 and Decision to Advance to Late Stage Development
November 19 2012
Supernus Receives Three Years of Market Exclusivity for Oxtellar XR™
November 15 2012
Insulet Ranked Among the Fastest Growing Companies in North America on Deloitte's 2012 Technology Fast 500™
November 14 2012
Acceleron Announces the Initiation of the Gynecologic Oncology Group Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Endometrial Cancer
November 13 2012
Cardioxyl Pharmaceuticals Raises $28 Million in Series B Financing Led by OrbiMed Advisors
November 12 2012
METHYLGENE ANNOUNCES CDN.$26.1 MILLION PRIVATE PLACEMENT
November 8 2012
NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
November 8 2012
Insulet Reports Third Quarter 2012 Results
November 8 2012
Amarin Reports Third Quarter 2012 Financial Results and Provides Update on Operations
November 8 2012
Boston Scientific to Acquire Vessix Vascular
November 7 2012
arGEN-X reveals the target and unique mechanism of action of its most advanced preclinical antibody at the PEGS Summit 2012
November 6 2012
Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
November 6 2012
Crown Bioscience, Inc. and Horizon Discovery, Ltd. announce the availability of X-MAN Cell Lines for In Vivo and In Vitro Drug Discovery Model Validation
November 1 2012
Pacira Pharmaceuticals, Inc. Reports $4.6 Million in Third Quarter EXPAREL® Revenue and Full Third Quarter 2012 Financial Results
October 22 2012
Good Start Genetics® Announces The Expansion of its Next-Generation DNA Sequencing – Based Carrier Screening Service
October 22 2012
Supernus Receives FDA Approval for Oxtellar XR(TM) in Epilepsy
October 22 2012
Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis
October 10 2012
METHYLGENE PROVIDES CLINICAL UPDATE ON ITS MGCD290 NOVEL ANTIFUNGAL THERAPEUTIC PROGRAM
October 9 2012
Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics
October 8 2012
Affimed raises € 15.5 million in a Series D financing round
October 8 2012
EXPAREL as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay
October 4 2012
RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody
October 4 2012
Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers
October 1 2012
Response Biomedical Corporation: Announces Acquisition of Worldwide Rights of Infectious Disease Testing due to Termination of 3M Agreements
October 1 2012
Aragon Pharmaceuticals Announces Clinical Results from Ongoing Phase II Trial Confirming Robust Anti-Tumor Activity and Tolerability of ARN-509 in Three Different Patient Populations of Castration Resistant
September 27 2012
Glaukos ranks #7 in the Wall Street Journal's Top 50 Venture-Funded Companies
September 27 2012
The Wall Street Journal Names Acceleron to “The Next Big Thing” List of Top 50 Start-Ups in the United States
September 27 2012
ROKA BIOSCIENCE RECEIVES AOAC-RI CERTIFICATION FOR 10 ADDITIONAL SALMONELLA MATRICES
September 27 2012
Acceleron and Collaborators Present Data on Potential Biomarkers for Metastatic Breast Cancer and Head and Neck Cancer at the “2012 Markers in Cancer” Conference
September 25 2012
Pacira Pharmaceuticals, Inc. Launches EXPAREL Pivotal Nerve Block Trial
September 24 2012
Response Biomedical Corporation Announces: Share Consolidation
September 24 2012
Biodel Awarded NIH Grant to Develop Glucagon Formulations for Use in Artificial Pancreas
September 20 2012
MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products
September 19 2012
Aragon Elected as 2012 Fierce 15
September 18 2012
Igenica appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer
September 18 2012
DFINE ANNOUNCES FULL U.S. COMMERCIAL RELEASE OF STARTUMOR ABLATION SYSTEM
September 17 2012
VESSIX RECEIVES THERAPEUTIC GOODS ADMINISTRATION (TGA) APPROVAL
September 17 2012
Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
September 17 2012
Complete Genomics and BGI-Shenzhen Announce Definitive Agreement to Merge
September 13 2012
Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
September 12 2012
Acceleron Founder Dr. Tom Maniatis To Receive The 2012 Lasker Award in Medical Science
September 6 2012
NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
September 4 2012
Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
August 28 2012
Aragon Pharmaceuticals Announces Appointment of Faheem Hasnain as Independent Director
August 15 2012
Whale Imaging Attracts $8 Million From OrbiMed
August 15 2012
Relypsa Announces $80 Million Private Financing Transaction
August 14 2012
Puma Biotechnology Reports Second Quarter 2012 Financial Results
August 10 2012
Supernus Pharmaceuticals Reports Second Quarter 2012 Financial Results
August 10 2012
ChemoCentryx Announces Financial Results for the Quarter Ended June 30, 2012
August 10 2012
Bonovo® Orthopedics, INC. Launches The First PEEK LATERAL INTERBODY FUSION CAGE In China
August 9 2012
Pacira Pharmaceuticals, Inc. Reports $2.3 Million in Second Quarter EXPAREL® Revenue and Full Second Quarter 2012 Financial Results
August 9 2012
Intercept Pharmaceuticals Closes $30 Million Series C Financing
August 8 2012
NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
August 8 2012
Insulet Reports Second Quarter 2012 Results
August 8 2012
Response Biomedical Corporation Announces Appointment of W.J. (Bill) Adams as CFO Corporate Secretary and Resignation of Richard A. Canote as CFO
August 8 2012
Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
August 8 2012
Biodel Reports Third Quarter Fiscal Year 2012 Financial Results
August 8 2012
Amarin Reports Second Quarter 2012 Financial Results and Provides Update on Operations
August 8 2012
Complete Genomics Reports Second Quarter 2012 Results
August 7 2012
Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
August 1 2012
Adimab and Mersana Announce Antibody-Drug Conjugate Alliance
July 26 2012
Response Biomedical Corporation Announces: Appointment of Jeffrey L. Purvin as Director & CEO and Resignation of Peter Thompson as Interim CEO
July 26 2012
Amarin Announces FDA Approval of Vascepa(TM) (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia
July 24 2012
Complete Genomics to Bundle Ingenuity Analysis and Interpretation Software With Whole Genome Sequencing
July 23 2012
Roka Bioscience Kicks Off Atlas On Tour, A Mobile Demonstration Vehicle For The Food Safety Industry, At IAFP
July 20 2012
Supernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer
July 16 2012
Response Biomedical Corporation receives funding from the Government of Canada to support RAMP® Point-of-Care platform
July 13 2012
Supernus Provides Update on the Launch of Its Two Epilepsy Products Trokendi XR(TM) and SPN-804
July 13 2012
Supernus Receives Tentative Approval of Trokendi XR(TM) From FDA
July 12 2012
Receptos Co‐Publishes Highest Resolution G‐Protein Coupled Receptor Structure
July 11 2012
Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with ViewRay System
July 11 2012
Complete Genomics Announces New Technology Developed to Set Standard for Clinical-Grade Genomes
July 10 2012
Athersys Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome
June 25 2012
Glaukos Corporation Announces FDA Approval Of The iStent Trabecular Micro‐Bypass
June 22 2012
Biodel Announces $18.5 Million Private Placement
June 14 2012
DFINE ANNOUNCES COMPLETION OF STAR™ TUMOR ABLATION SYSTEM PHASE I RELEASE
June 12 2012
Igenica, Inc. closes $33 million in Series C funding
June 8 2012
Biodel Obtains Exclusive License to Aegis Therapeutics' Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
June 8 2012
ChemoCentryx Announces Peer-Reviewed Publication of Positive Phase 2 Clinical Data with CCX354, a Novel Inhibitor of Chemokine Receptor CCR1 in Patients with Rheumatoid Arthritis
June 5 2012
New Data Quantifying the Effects of Opioid Use on Patient Care and Economic Outcomes Presented at Key Medical Meetings
June 4 2012
Astellas and Ambit Initiate Phase 2b Dose Finding Study of Quizartinib as Monotherapy in Relapsed or Refractory Acute Myeloid Leukemia
June 2 2012
Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting
May 30 2012
ViewRay Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System
May 17 2012
Pacira Pharmaceuticals, Inc. to Be Added to NASDAQ Biotechnology Index
May 17 2012
Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
May 9 2012
Whole Genome Sequencing in Type 2 Diabetes Genetic Study
May 9 2012
Selecta Biosciences Receives 2012 Edison Award’s Gold Medal for Best Pharmaceutical Product Innovation
May 8 2012
Complete Genomics Builds Asia-Pacific Presence, Signs Distributor Agreements in Australia, China, Japan and Korea
May 4 2012
Supernus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
May 3 2012
Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing
May 2 2012
Roka Bioscience Atlas System Supports Efficient, Innovative Food Pathogen Testing at QC Laboratories
May 2 2012
Biodel’s Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
April 26 2012
Rempex Pharaceuticals Appoints Jennifer Cayer New Chief Operating Officer
April 26 2012
DFine Awarded National Contract by Premier Healthcare Alliance
April 25 2012
Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
April 24 2012
Attracts Seasoned Team, Including CEO, CFO, and CMO, Changes Name to Keystone Heart Ltd.
April 16 2012
Puma Biotechnology Cleared for Quotation on OTCBB and OTC LINK
April 15 2012
Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations
April 13 2012
Response Biomedical Corporation Announces: Agreement with Jeffrey L. Purvin to become Chief Executive Officer
April 11 2012
Insulet Expands International Distribution Partnership with Ypsomed
April 9 2012
Pacira Pharmaceuticals, Inc. Announces Commercial Availability of EXPAREL
April 3 2012
Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma
April 3 2012
Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma
April 2 2012
Methylgene Presents Preclinical Data for MGCD265 at the AACR Annual Meeting
April 2 2012
April 2 2012
Adimab completes Series F Financing – Acquires New Research Facility to Accommodate Growth
March 29 2012
Complete Genomics Now Accepts DNA Obtained From Saliva for Whole Human Genome Sequencing
March 28 2012
Sientra Raises $65 Million in a Series C Financing to Support Commercialization of its FDA-Approved Silicone Breast Implants
March 27 2012
Latest Research Further Validates DFine RF-TVA Therapy for Treatment of Vertebral Compression Fractures
March 21 2012
Roka Bioscience Awarded AOAC-RI Certification for Atlas Salmonella Detection Assay
March 14 2012
DFine Announces First US Patient Treated With the STAR Ablation System
March 13 2012
ViewRay Closes Round of Series C Financing
March 9 2012
Sientra receives FDA approval of its Silimed-brand portfolio of round and shaped silicone breast implants
March 6 2012
Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers
March 5 2012
Anthera Pharmaceuticals Completes Interim Analysis of PEARL-SC Clinical Trial with Blisibimod
February 23 2012
First Patients Treated in Hypertension Clinical Study Using the Vessix Vascular Balloon Catheter Renal Denervation System
February 16 2012
Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science
February 16 2012
Complete Genomics Launches Genomic Discovery Software Partners Program
February 15 2012
Insulet Announces Global agreement With LifeScan, Inc to Integrate Their OneTouch Blood Glucose Monitoring Technologies Into the OmniPod Insulin Pump
February 13 2012
Mayo Clinic Selects Complete Genomics to Provide Outsourced Whole Genome Sequencing
January 20 2012
Committee for Orphan Medicinal Products Recommends Orphan Designation for Biodel’s Stabilized Glucagon for the Treatment of Congenital Hyperinsulinism
January 19 2012
Complete Genomics Publishes Paper Describing Its Informatics Approach for High-Accuracy Whole Human Genome Sequencing
January 17 2012
Roka Bioscience Awarded AOAC-RI Certification for Roka Listeria Detection Assay
January 11 2012
Three Adimab Antibodies Enter Human Clinical Trials
January 9 2012
Complete Genomics Announces Shipment of Approximately 3,000 Genomes in 2011
January 6 2012
Roka Bioscience Secures $47.5 Million In Series D Financing
January 4 2012
MethylGene Announces the Appointment of Rachel Humphrey, MD as Executive Vice President and Chief Medical Officer
December 28 2011
Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)
December 23 2011
Acceleron Secures $30M Private Financing
December 20 2011
MacroGenics Receives Milestone Payment as Part of its Global DART Alliance with Boehringer Ingelheim
December 19 2011
Pacira Pharmaceuticals, Inc. Announces Results from EXPAREL Pivotal Trial Published in Diseases of the Colon & Rectum
December 19 2011
Pall Corp. Signs Agreement to Acquire Life Sciences Innovator ForteBio
December 14 2011
Anthera Announces Completion of Safety Review by DSMB for VISTA-16
December 9 2011
Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
December 6 2011
Dfine Receives Medical Device License For The StabiliT System in Canada and Mexico
December 1 2011
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
December 1 2011
Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEARL-SC Study
November 28 2011
Supernus Pharmaceuticals Initiates Phase IIb Clinical Trial for SPN-810 in Impulsive Aggression
November 23 2011
http://www.pumabiotechnology.com/pr20111123.html
November 18 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
November 15 2011
November 9 2011
Rempex Announces Series B Financing of up to $67.5 Million
November 8 2011
DFINE, Inc. Announces Close Of $25 Million Financing
November 8 2011
Cerapedics Granted Patent Protecting the Method of Manufacture for i-FACTOR™ Biologic Bone Graft in Lyophilized Forms
November 3 2011
Complete Genomics Launches Comprehensive Cancer Sequencing Service at ICHG/ASHG 2011
November 2 2011
DFINE Awarded U.S. Department of Veterans Affairs Five-Year Contract for StabiliT Vertebral Augmentation System
October 31 2011
Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL(TM) For Postsurgical Pain Management
October 27 2011
Selecta Announces $47.25 Million Financing to Broaden R&D Capabilities and Accelerate Pipeline of Vaccines and Immunotherapies
October 27 2011
RUSNANO invests in Selecta Biosciences and BIND Biosciences to develop and commercialize vaccines and cancer drugs through expanded operations in Russia
October 24 2011
Anthera Announces Last Patient Enrolled in PEARL-SC Study
October 19 2011
Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL(TM) Compared to Bupivacaine HCl
October 19 2011
Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin® Pipeline Development
October 18 2011
Methylgene Receives FDA IND Approval to Begin a Phase II Clinical Trial with MGCD290, a Novel Antifungal Product Candidate
October 12 2011
Good Start Genetics Announces Validation Study of Next-Gen DNA Sequencing Test for Oral Presentation at the 2011 American Society of Reproductive Medicine (ASRM) Annual Meeting
October 11 2011
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
October 5 2011
Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational PanHER Inhibitor; Closes $55 Million Private Placement and Completes Merger
October 3 2011
Scripps Health and Complete Genomics Announce Collaboration Aimed at Unlocking Genetic Secrets of Healthy Aging
September 13 2011
Acceleron Initiates Phase 1 Study of ACE-536
September 12 2011
superDimension Raises $11 Million in Equity Financing
September 9 2011
Pacira Pharmaceuticals, Inc. Expands EXPAREL(TM) Commercial Team Infrastructure
September 8 2011
Complete Genomics Partners With Inova Health System to Sequence the Genomes of 500 Babies and Their Parents
September 6 2011
FierceBiotech Names Selecta Biosciences a 2011 Fierce 15 Biotech
August 31 2011
Selecta Biosciences Awarded Subcontract to Develop a Synthetic Nanoparticle Vaccine for Malaria
August 30 2011
Amnis Acquired by EMD Millipore – Expands Growth Potential
August 29 2011
Adimab Announces New Discovery Programs with Biogen Idec and Novo Nordisk
August 24 2011
Complete Genomics to Sequence More Than 1,000 Additional Genomes for National Cancer Institute’s Pediatric Cancer Study
August 8 2011
Roka Bioscience Introduces Fully Automated Molecular Solution for Food Pathogen Testing at IAFP Annual Meeting
August 8 2011
Enobia Pharma Raises US $40 million
August 3 2011
VESSIX VASCULAR COMPLETES $23 MILLON FINANCING
August 3 2011
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program
July 20 2011
superDimension ENB: New technology helps diagnose lung nodules
July 5 2011
Study Suggests Lower Cement Leakage Rate with DFINE Radiofrequency Targeted Vertebral Augmentation™ (RF-TVA) in The Treatment of Vertebral Compression Fractures
June 30 2011
Sheila Gujrathi, M.D. Named Chief Medical Officer of Receptos
June 29 2011
NLST results published -Reduced Lung-Cancer - Mortality with Low-Dose Computed Tomographic Screening Better Evidence about Screening for Lung Cancer
June 29 2011
Complete Genomics Launches Cancer Grant Program
June 28 2011
Relypsa Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease
June 28 2011
DFINE Announces First Patient Treated with Star™ System in a Clinical Trial to Evaluate Targeted Radiofrequency Ablation Therapy for Spinal Tumors
June 27 2011
Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
June 26 2011
Bonovo® Orthopedics, Inc. Launches New Division Focused on Joint Reconstruction
June 14 2011
Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL(TM) PDUFA Target Date by Three MonthsPacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL(TM) PDUFA Target Date by Three Months
June 13 2011
Response Biomedical Receives Decision Regarding CLIA Waiver for RAMP NT-proBNP Assay for Diagnosis of Heart Failure (HF)
June 9 2011
The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes
June 9 2011
Selecta Biosciences Appoints Peter Keller as Vice President of Business Development and Alliance Management
June 9 2011
Ambit Biosciences and Astellas announce upcoming presentation of AC220 data at the 16th annual Congress of the European Hematology Association
June 8 2011
Study Reports Optimum Safety and Efficacy of the Stabilit® Vertebral Augmentation System in the Treatment of Upper Thoracic Vertebral Compression Fractures Due to Multiple Myeloma
June 8 2011
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
June 8 2011
Fortebio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
June 6 2011
DFINE, Inc. Announces Prospective Clinical Trial for Breakthrough Therapy to Treat Spinal Fractures Caused by Multiple Myeloma
June 2 2011
Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
June 2 2011
Celgene and Acceleron Initiate Phase 2/3 Study of ACE-011 (sotatercept) to Treat Chemotherapy-Induced Anemia in Patients with Lung Cancer
June 1 2011
Complete Genomics Announces Closing of Public Offering and Exercise of Over-Allotment Option
May 31 2011
Biolex Presents Final Phase 2B Results at EASL Highlighting Tolerability Advantages of Locteron® in Treatment of HCV
May 31 2011
Brandon Regional Hospital Offers New Electromagnetic Navigation Bronchoscopy ™ Procedure to Diagnose and Plan Treatment for a Lesion Deep in the Lung
May 31 2011
Biolex Presents Phase 2B Results at EASL Showing Reduced Rates of Depression in HCV Patients Treated with Locteron®
May 25 2011
Complete Genomics Announces Pricing of Public Offering
May 24 2011
DFINE StabiliT Vertebral Augmentation System Product Innovation Offers Physicians Improved Flexibility and Easy-Of-Use for the Treatment of Spinal Fractures
May 24 2011
DFINE, Inc. Offers Advanced Treatment for Immediate Pain Relief and improved Quality of Life for Patients Suffering From Spinal Fractures Due to Osteoporosis
May 23 2011
Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin PRS-080 Hepcidin Antagonist Drug Program
May 19 2011
Relypsa Adds Key Leadership Positions to Support Late-Stage Development and Pre-Launch Commercial Activities
May 18 2011
Landmark Patents Issued for ViewRay Technology
May 16 2011
Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
May 13 2011
Amnis Introduces New FlowSight Imaging Flow Cytometer
May 11 2011
Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
May 11 2011
Response Biomedical Corporation Announces First Quarter Results
May 9 2011
Acceleron Pharma Presents Anabolic Bone Effects of ACE-661 at International Scientific Meeting
May 4 2011
Response Biomedical Corporation Enters Into Exclusive Canadian Distribution Agreement with Fisher Scientific Company
May 3 2011
Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
May 2 2011
EA chosen for BioExcellence Award at Bangalore Bio
April 28 2011
Response Biomedical Corporation Receives SFDA Registration of Ramp 200
April 28 2011
Data Published in Blood Demonstrate Potent Activity of MacroGenics’ Proprietary DART Technology
April 26 2011
Affimed Therapeutics AG appoints Dr. Adi Hoess as Chief Commercial Officer
April 20 2011
Frances K. Heller Joins Adimab Board of Directors
April 18 2011
Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
April 12 2011
Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin Therapeutics
April 11 2011
Prospective, Randomized, Controlled Trial Demonstrates 98% Fusion Rate at 6-months and 12-months with i-FACTOR™ Biologic Bone Graft and Superiority versus Autograft in Single- and Multi-Level PLIF Spine Surgery
April 6 2011
http://www.completegenomics.com/news-events/press-releases/Complete-Genomics-Adds-29-High-Coverage-Complete-Human-Genome-Sequencing-Datasets-to-its-Public-Genomic-Repository--119298369.html
April 6 2011
Complete Genomics Adds 29 High-Coverage, Complete Human Genome Sequencing Datasets to its Public Genomic Repository
April 5 2011
Acceleron Presents Positive Results from Phase 1 Study of ACE-041 in Patients with Advanced Cancer
April 4 2011
superDimension Receives FDA 510(k) Clearance for Marker Delivery Kit
March 31 2011
Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
March 31 2011
Biolex Presents Phase 2B Results at EASL Showing Reduced Rates of Depression in HCV Patients Treated with Locteron®
March 31 2011
Biolex Presents Final Phase 2B Results at EASL Highlighting Tolerability Advantages of Locteron® in Treatment of HCV
March 28 2011
EA strengthens clinical research presence in Nordic countries by acquiring majority stake in aCROnordic
March 27 2011
Well-Funded Device Startup Eyes Big Global Market
March 25 2011
EA’s short term goal is to become No. 1 Indian CRO
March 15 2011
Cerenis Initiates Phase 2 Study of Lead Product candidate, CER-001, in Patients with Acute Coronary Syndrome
March 14 2011
Complete Genomics Customers Can Now Use DNAnexus’ Cloud-Based Informatics Solution to Study Their Human Genome Sequencing Data
March 10 2011
Glaukos ranks #19 in the Wall Street Journal’s top 50 Venture-Funded Companies
March 10 2011
Biolex to Present Final Phase 2B Result at EASL for Locteron Next-Generation Controlled-Relase Interferon for HCV
March 9 2011
University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System
March 7 2011
Using GPS Technology in Weston to Fight Lung Cancer
March 2 2011
Pacira Pharmaceuticals' EXPAREL(TM) Data to be Featured at 2011 ASCPT 112th Annual Meeting
March 2 2011
Insulet signs distribution deal with Glaxo
February 28 2011
Arsanis, Inc Announces Series A Financing with OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences
February 24 2011
Enobia Announces Completion of Enrollment in Third Phase II Hypophosphatasia Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
February 23 2011
ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
February 22 2011
Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine Tri-Conference
February 21 2011
Complete Genomics Selected by MIT’s Technology Review for Top 50 Innovative Companies List
February 15 2011
FORTEBIO LAUNCHES NEW OCTET® RED96 SYSTEM AND DIP AND READ™ PROTEIN L BIOSENSOR
February 8 2011
Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
February 3 2011
Complete Genomics is Publicly Releasing a Large Sequencing Dataset—60 Complete, High-coverage Human Genomes—for Study by the Global Research Community
February 1 2011
Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
January 27 2011
First subject dosed in Phase 1 Single Ascending and Multiple Ascending Dose Safety Study
January 27 2011
Ecron Acunova adds on stem cell therapy and diabetes centre to conduct studies for global and Indian sponsors
January 17 2011
Ecron Acunova CRO and Newcastle University Collaborate in Clinical Research
January 17 2011
Ecron Acunova acquires stake in SEA CRO and commences direct operation
January 17 2011
Ecron Acunova CRO expands its clinical research centre for drug development 80 bed drug research centre opens at Ecron Acunova CRO in Mangalore
January 11 2011
The Institute for Systems Biology Places a Third Order for Sequencing Services With Complete Genomics, Includes 615 Genomes
January 10 2011
Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration
January 10 2011
Boehringer splashes out on bispecific antibody platforms
January 10 2011
Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
January 6 2011
Receptos Announces Exclusive Collaboration with Lilly
January 6 2011
Receptos Announces License to Advance Structure-Based Drug Discovery for High-Value G-Protein Coupled Receptor (GPCR) Targets
January 6 2011
Complete Genomics Releases Genome Sequences From a Well-Studied Yoruba Family
January 4 2011
Response Biomedical Corporation Enters Into Exclusive Italian Distribution Agreement with Cremascoli & Iris, s.r.l.
January 1 2011
Siphon Effects on Continuous Subcutaneous Insulin Infusion Pump Delivery Performance
December 30 2010
Supernus seeks $100 million in public offering
December 27 2010
Bonovo Orthopedics Gathers $10 Million Series C Led by OrbiMed To Fuel China Expansion
December 23 2010
Bonovo Orthopedics, Inc. Closes Series C Financing Led by OrbiMed Asia Partners
December 20 2010
Ambit Biosciences initiates two Phase I Clinical Trials
December 17 2010
MacroGenics hits winning target
December 17 2010
Singulex Receives US Patent for Cardiovascular Biomarker Assay, Begins Planning FDA Submission
December 17 2010
Complete Genomics Reports Third Quarter Results
December 15 2010
Adimab Announces New Discovery Programs with Eli Lilly, Genentech and Human Genome Sciences
December 15 2010
Affimed enrolls first patients in Phase I Hodgkin’s Lymphoma Study
December 14 2010
Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL New Drug Application for Pain Management
December 14 2010
Insulet Announces Early Repayment of $32.5 Million Facility Agreement
December 14 2010
Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent
December 9 2010
Anthera Announces Update Call Regarding Vial Problems
December 9 2010
December 7 2010
Insulet Corporation Announces Sale of 3,000,000 Shares
December 7 2010
Varespladib Receives 2010 European Society Pediatric Research Award
December 6 2010
New Technology for Diagnosing Lung Cancer
December 2 2010
Faheem Hasnain Named President and Chief Executive Officer
December 1 2010
Lung Tumor Technology Upgraded at Local Center
November 29 2010
Acceleron Appoints Kevin F. McLaughlin as Senior Vice President and Chief Financial Officer
November 19 2010
Acceleron Announces Interim Findings from the ACE-041 Phase 1, First-in-Human Clinical Trial at 22nd EORTC-NCI-AACR Symposium
November 15 2010
Affimed enrolls first patients in Phase I Hodgkin’s Lymphoma Study
November 11 2010
Complete Genomics Announces Pricing of Initial Public Offering
November 9 2010
Biolex Therapeutics Names Kurt Graves Executive Chairman as Company Prepares for Phase 3 Trials and Commercialization of Locteron® in Hepatitis C
November 5 2010
AMBIT BIOSCIENCES FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING
November 2 2010
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
November 1 2010
NeurAxon, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference November 16, 2010
November 1 2010
BIOLEX PRESENTS AT AASLD MEETING SIGNIFICANT TOLERABILITY ADVANTAGES OF LOCTERON®, ITS NEXT-GENERATION INTERFERON FOR HEPATITIS C
October 31 2010
NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy in Acute Migraine
October 28 2010
Biolex Announces Locteron® SVR12 Results and Safety/Tolerability Advantages in SELECT-2 Hepatitis C Trial -Additional Tolerability Results from Two Phase 2b Trials of Locteron to be Presented in Late-Breaker Session at AASLD Conference on November 1, 2010
October 26 2010
NeurAxon's NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover
October 26 2010
MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
October 26 2010
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
October 26 2010
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
October 21 2010
Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing
October 20 2010
Insulet Ranked Third Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500(TM)
October 20 2010
Ismail Kola Elected to Athersys Board of Directors
October 15 2010
Inhibitex Completes Enrollment in Phase II Clinical Trial of FV-100 in Shingles Patients
October 14 2010
NeurAxon Named One of Canada’s Top 10™ Life Science Companies
October 13 2010
Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
October 11 2010
Gelesis Presents Mechanistic Data Supporting its Novel Clinical Stage Obesity Treatment at Obesity 2010
October 5 2010
Complete Genomics Expands CGA Tools Software Suite to Accelerate Biological Discovery From Complete Human Genome Sequencing Data
October 4 2010
DFine Announces FDA 510(k) Clearance of New Radiofrequency Ablation System for Metastatic Spinal Lesions
September 28 2010
Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics
September 24 2010
Enobia Reports Positive Results for Phase II Trial of ENB-0040 in Juvenile Hypophosphatasia
September 15 2010
Adimab makes FierceBiotech's "Fierce 15" List for 2010
September 9 2010
Acceleron Pharma Announces a $498 Million Joint Development and Commercialization Agreement with Shire on Novel Muscle Therapeutics for Orphan Diseases
September 8 2010
Enobia Provides Update on Progress with ENB-0040, a Bone-targeted Enzyme Replacement Therapy for Hypophosphatasia
August 25 2010
ViewRay Secures Series C Financing
August 19 2010
Acceleron Pharma Receives FDA Orphan Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy
August 16 2010
Selecta Biosciences Appoints Werner Cautreels, Ph.D., as Company's First CEO
August 10 2010
Amarin Reports Q2 2010 Results
August 3 2010
Siteman Cancer Center to Receive First ViewRay Radiation Therapy System
July 30 2010
Complete Genomics Files Registration Statement for Proposed Initial Public Offering
July 29 2010
Insulet Corp. Revenue Increases 57% Year over Year; More than 20,000 Customers Now Using the OmniPod System
July 28 2010
Response Biomedical Corporation Closes $8 Million Private Placement
July 26 2010
Cerenis Therapeutics raises EUR 40 million in series C financing
July 23 2010
NxStage Reports Record Second Quarter 2010 Financial Results and Raises Revenue Guidance For 2010
July 9 2010
Adimab Announces Fifth Major Pharma Partnership in First Year After Launch
June 15 2010
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
April 12 2010
Inhibitex Reports Results of Interim Analysis of Phase II Clinical Trial of FV-100
March 29 2010
Enobia Presents Results from Hypophosphatasia Impact Patient Survey
February 25 2010
NxStage Reports Fourth Quarter and Full-Year 2009 Financial Results That Exceed Company Guidance
February 9 2010
Insulet Reports Fourth Quarter Results: FY 2009 Revenue Increases 83%
January 27 2010
Supernus Announces Positive Results from Phase IIa Clinical Trial for SPN 810
January 22 2010
Complete Genomics Named a Red Herring Global 100 Award Winner
January 11 2010
Volcano Corporation Announces Record Revenues for Fourth Quarter 2009
January 11 2010
ForteBio Launches New Dip and Read™ Residual Protein A Detection Kit
January 4 2010
Pieris Appoints a new CEO